Catheter-based adenovirus-mediated local intravascular gene delivery of a soluble TGF-b type II receptor using an Infiltrator in porcine cornary arter by �옣�뼇�닔
EXPERIMENTAL and MOLECULAR MEDICINE, Vol. 34, No. 4, 299-307, September 2002Catheter-based adenovirus-mediated local intravascular gene 
delivery of a soluble TGF-β type II receptor using an Infiltrator in 
porcine coronary arteries: efficacy and complications
Ick-Mo Chung1,6, Hikaru Ueno2, Youngmi Kim
Pak3, Joon-Woo Kim3, Dong-Hoon Choi4, Gil Ja
Shin1, Woo-Ick Yang5 and Yang soo Jang4
1 Division of Cardiology, Ewha Womans University School of Medi-
cine, 70 Jongro-Gu, Jongro-6 Ga, Seoul 110-783, Korea
2 Department of Biochemistry and Molecular Pathology, University
of Occupational and Environmental Health, Kitakyusyu, Japan
3 Division of Metabolic Disease, Korea National Institute of Health,
Seoul, Korea
4 Division of Cardiology,  Korea National Institute of Health, Seoul,
Korea
5 Department of Pathology, Yonsei University School of Medicine,
Seoul, Korea
6 Corresponding author: Tel, +82-2-760-5076;
Fax, +82-2-762-7756; E-mail, ickmo@mm.ewha.ac.kr 
Accepted 16 September 2002
Abbreviations: TGF-β, transforming growth factor β; ECM,  extra-
cellular matrix; AdTβ-ExR, adenovirus expressing an entire ecto-
domain of the TGF-β type II receptor; AdCALacZ, adenovirus
expressing β-galactosidase; pfu, plaque formation units; LAD, left
anterior descending artery; FITC, fluorescein isothiocyanate; LCX,
left circumflex artery; RCA, right coronary artery; RT-PCR, reverse
transcription PCR; X-gal, 5-bromo-4-chloro-3-indolyl-β−D-galacto-
pyranoside
Abstract
Enhanced extracellular matrix (ECM) accumulation is
an important finding in human restenotic arterial
neointima after angioplasty. Transforming growth
factor β1(TGF-β1) is known to regulate the synthesis
and turnover of a variety of ECM components, and
may play an important role in restenosis. Recombi-
nant adenoviral vector expressing an ectodomain of
the TGF-β type II receptor fused to the human immu-
noglobulin Fc portion (AdTβ-ExR) inhibits the action
of TGF-β probably either by adsorbing TGF-β or by
acting as a dominant negative receptor. We carried
out a catheter-based local adenovirus mediated gene
delivery using an Infiltrator in porcine coronary arter-
ies to know the pattern of gene expression, efficacy
and procedural complications. Twenty four coronary
arteries in 13 pigs were used for intravascular gene
delivery by intramural injection with either AdTβ-ExR
or adenovirus expressing β-galactosidase (AdCA-
LacZ). Direct immunofluorescent staining and
reverse transcription polymerase chain reaction (RT-
PCR) were used for detection of type II TGF-β recep-
tor and its mRNA respectively. X-Gal histochemistry
was performed to identify β-galactosidase. Both sol-
uble TGF-β receptor and β-galactosidase were
expressed locally in the media and adventita at
injected arterial segments without any significant
dissemination to remote area. Intravascular gene
transfection performed with various titer of each ade-
noviral vector showed that AdTβ-ExR of 5x108 pfu
and AdCALacZ of 2.5 x 108 pfu were the minimum
titer for the expression of each transgene. Infiltration
of CD3 positive T cells was detected by immunohis-
tochemical staining in the area of each transgene
expression, and tends to decrease over time after
gene delivery. Pathological study of 24 treated arter-
ies showed complications such as disruption of
external elastic lamina with hemorrhage (n = 4), min-
imal disruption of internal elastic lamina and endot-
helial layer, and medial thickening. In conclusion,
catheter-based local intravascular gene delivery of
adenoviral vector is feasible and effective in a
selected artery, but must be undertaken with caution
due to possible lethal complications. Local delivery
of soluble TGF-β type II receptor in this way may pro-
vide an effective intravascular gene therapy to inhibit
TGF-β signal pathway without any significant sys-
temic side effect. 
Keywords: gene therapy, local delivery, transforming
growth factor β receptors, extracellular matrix, coronary
restenosis, catheterization
Introduction
Although percutaneous coronary intervention is currently
widely accepted as a treatment of coronary artery
disease, restenosis rate is still relatively high. Patho-
logical analysis of human coronary arterial restenotic
neointima after stenting showed that extracellular matrix
(ECM) accumulation plays an important role in
neointima formation (Strauss et al., 1992; Chung et al.,
2002). Transforming growth  factor β1 (TGF-β1) is
known as a multifunctional cytokine that regulates cell
proliferation and differentiation, angiogenesis, and
synthesis of a variety of ECM components such as
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(Schönherr et al., 1991; Chen et al., 1993; Nabel et al.,
1993; Schönherr et al., 1993; Dijike et al., 1994;
Yamamoto et al., 1996; Schulick et al., 1998; McCaffrey
et al., 2000). And its expression was significantly higher
in restenotic lesions compared with primary lesions
(Nikol et al., 1992). Blocking TGF-β1 activity with
neutralizing antibody fol-lowing vascular injury decreases
ECM accumulation and suppressed intimal hyperplasia in
the rat model of arterial injury (Wolf et al., 1994). Most cells
have three types of TGF-β receptors (type I, type II, and
type III) at the cell surface, and both type I and type II
receptor are necessary for all tested biological activity of
TGF-β, whereas type III is not known to mediate any of the
known biological activity of TGF-β (Chen et al., 1993; Dijike
et al., 1994). Type II receptor is a member of the
transmembrane receptor serine-threonine kinase family,
and TGF-β signals through a heteromeric complex
between the type I and type II receptors (Chen et al., 1993;
Bassing et al., 1994; Dijike et al., 1994). Binding of TGF-β
to the type I receptor requires the presence of the type II
receptor, whereas type II receptor binds TGF-β
independently (Bassing et al., 1994; Dijike et al., 1994).
Type I receptor requires the presence of a functional type II
TGF-β receptor to signal, and trans-phosphorylation of the
type I receptor by the type II receptor seems to be essential
for signaling (Bassing et al., 1994; Yamamoto et al., 1996).
As a consequence of developments in the field of
molecular biology, strategies targeting TGF-β has been
recently developed. For example, ribozyme oligonucleo-
tides cleave the mRNA of TGF-β, leading to decreased
expression (Yamamoto et al., 2000). An adenoviral
vector expressing the ectodomain of the type II TGF-β
receptor (AdTβ-ExR) inhibits the action of TGF-β both in
vitro and in vivo (Smith et al., 1999; Sakamoto et al.,
2000). This soluble receptor is also known to be able to
reach remote areas by means of systemic circulation.
Recent animal trials using either ribozyme oligonucleo-
tides or soluble type II TGF-β receptor to inhibit TGF-β in
vascular injury model showed beneficial effects by inhi-
biting either neointima or negative vascular remodeling
(Smith et al., 1999; Yamamoto et al., 2000; Kingston et
al., 2001). These studies used different gene transfer
methods including systemic intravenous injection (Smith
et al., 1999), retention of agents in surgically isolated
vascular segment (Yamamoto et al., 2000), or Infilt-rator
(Kingston et al., 2001). Local delivery of agent without
any significant systemic untoward effect would be
preferred to systemic injection for gene therapy in the
local vascular lesion. Gene transfection using channe-
ledballoon angioplasty catheter which allows low pres-
sure local agent delivery through perforated channels
has low efficiency in gene delivery (Feldman et al.,
1996). Thus it is conceivable that gene transfection by
transient retention of adenovirus in the isolated vascular
segment probably has very low gene transfection
efficiency. The Infiltrator is a balloon catheter with 21
injector ports in three lines designed for direct intramural
injection of the desired agent. Previous studies using an
Infiltrator, in general, agree that it is an effective tool for
intravascular drug or gene delivery, but knowledge
about efficacy of gene expression at different titer of virus
vector and about procedural complication is limited. 
Since local blockade of TGF-β seems to have the-
rapeutic potential in the vascular pathology, we carried
out catheter-based adenovirus mediated local intrava-
scular delivery of a soluble TGF-β type II receptor using
an Infiltrator in a porcine coronary arterial model to know
about the expression pattern of this transgene,
inflammatory reaction, feasibility and complications of
catheter-based gene therapy. And we also tried to
identify the minimum titer of virus vector with which the
soluble receptor can be expressed in the selected
arterial segment without any significant dissemination
into remote areas. 
Materials and Methods
Recombinant adenovirus vectors
Replication-defective E1- and E3- recombinant adeno-
virus expressing either an entire ectodomain of the TGF-
β type II receptor fused to the human immunoglobulin Fc
portion (AdTβ-ExR) or β-galactosidase (AdCALacZ)
under a CA promoter, composed of cytomegalovirus
enhancer and chicken β-actin promoter, was constructed
as described previously (Ueno et al., 1995; Qi et al.,
1999). TGF-β type II soluble receptor is known to be
secreted from AdTβ-ExR-infected cells, binds to TGF-β
and inhibits TGF-β signaling (Sakamoto et al., 2000).
Both AdTβ-ExR and AdCALacZ were used as adenoviral
vectors for gene delivery in porcine coronary arteries.
The titer of virus was quantified by a plaque formation
assay using 293 cells and expressed as plaque
formation units (pfu).
Local gene delivery at porcine coronary artery
Thirteen domestic female pigs (2-3 month old, weighing
25-30 kg) underwent coronary artery intravascular gene
delivery using an Infiltrator (Interventional Technologies,
San Diego, CA). All animal care and handling were
performed in accordance with the guideline specified by
the National Institute of Health Guide for the Care and
Use of Laboratory animals and were approved by the
Animal Care and Use Committee of Yonsei University.
Animals took 100 mg of aspirin and 75 mg of clopidogrel
24 h before procedure and continued to take these
medication until sacrifice. Before anesthesia, pigs
subjected intramuscular injection of atropine (0.04 mg/
kg) and rompun (2 mg/kg). After endotracheal intu-
bation, anesthesia was induced by inhalation of 2.5%
enflurane. Heparin (3,000 IU) was injected intravenously
In vivo gene delivery using Infiltrator 301before coronary arterial intervention. An 8 F Judkins right
coronary artery guide catheter was inserted through the
left carotid artery. Coronary arterial segments in the left
anterior descending (LAD), left circumflex (LCX), or right
coronary artery (RCA) feasible for intravascular gene
delivery using an Infiltrator (3.0-3.5 mm) were selected.
An infiltrator was used for injection of 400 µl of each
adenoviral vector following inflation of the Infiltrator to 2
atmosphere. Coronary angiogram was performed at both
before and immediately after gene delivery. Intracoronary
injection of isosorbide dinitrate (200 µg) was performed
before angiogram to relieve any possible vasospasm. To
identify optimal titer of adenoviral vector for effective gene
transfer, three different titers of AdTβ-ExR (1 x 108,
5 x 108, or 1 x 109 pfu in 400 µl PBS) and two different
titers of AdCALacZ (2.5 x 107 or 2.5 x 108 pfu in 400 µl
PBS) were randomly injected into each coronary arterial
segment in three pigs (No. 1-3 in Table 1). The rest of pigs
undertook intravascular injection of adenoviral vector or
PBS as shown in Table 1. After gene delivery, catheters
were removed, and left carotid artery was ligated. 
To identify the efficiency of gene transfer, three pigs
(No. 1-3 in Table 1) were sacrificed at 1 week after gene
delivery. Three pigs (No. 4, 7, 12 in Table 1) died during
the procedure due to complications, and seven pigs
were sacrificed at 4 weeks after gene delivery. Coronary
arterial segments from each adenovirus injected site
were retrieved. Thoracic aorta as well as remote
coronary arterial segments were used as negative
control tissues. Coronary arteries dissected at 1 week
after gene delivery were snap-frozen in liquid nitrogen,
and were divided into two pieces: one embedded in
OCT for cryostat sectioning and the other kept in 70oC
until RNA assay. Arterial specimens dissected from the
rest of pigs were pressure-fixed in situ with 4%
formaldehyde, and embedded in paraffin. 
Histochemical analysis for β-galactosidase
Pigs were sacrificed 1 week after gene delivery with a lethal
dose of sodium pentobarbital. Coronary arterial segments
were excised, fixed in PBS containing 2% formaldehyde
and 0.2% glutaraldehyde for 2 h at 4oC, embedded in OCT
compound, and subjected to cryostat section at 20 µm
thickness. Expression of β-galactosidase was evaluated by
incubation at 37oC with the substrate 5-bromo-4-chloro-3-
indolyl-β-D-galactopyranoside (X-gal; Sigma, St. Louis,
Table 1. Results of gene delivery using an Infiltrator and subsequent stent deployment in porcine coronary arteries. No, number; AdTβ-ExR, adenovirus vector
expressing soluble TGF-β type II receptor; AdCALacZ, adenovirus vector expressing β-galactosidase; PBS, phosphate buffered saline; φ, diameter; atm,
atmosphere; Di, dissection; FD, failure of deballooning; Sp, spasm; VT, ventricular tachycardia
No Sites Vector Titer
(Pfu)
Lumen Φ (Mm) Complication Outcome
1 m-LAD
m-RCA
AdTβ-ExR
AdCALacZ
1x108
2.5x107
3.0
3.5
alive
2 m-LAD
p-LCx
AdTβ-ExR
AdCALacZ
5x108
2.5x108
3.0
3.5 Di
alive
3 p-LAD
d-LAD
AdTβ-ExR
AdTβ-ExR
5x108
1x109
3.5
3.5
alive
4 p-RCA
p-LAD
AdTβ-ExR 
AdCALacZ
1x109
1x109
3.5
3.5 Di/Sp/VT death
5 p-LCx
p-RCA
AdTβ-ExR 
AdCALacZ
1x109
1x109
3.5
3.5
alive
6 m-LAD
d-RCA
AdTβ-ExR 
AdCALacZ
1x109
1x109
3.0
3.0
alive
7 p-LAD AdTβ-ExR 1x109 3.0 Di/Sp/VT death
8 m-LAD
m=RCA
AdTβ-ExR 
PBS
1x109 3.0
3.0
alive
9 m-LAD
d-RCA
AdTβ-ExR
PBS
1x109 2.5
2.5 Sp/VT
alive
10 m-RCA
d-LCx
AdTβ-ExR 
PBS
1x109 3.0
3.0
Sp alive
11 p-RCA
p-LAD
AdTβ-ExR
PBS
1x109 3.0
3.0
Sp alive
12 p-LCX AdTβ-ExR 1x109 3.0 FD/Sp/VT death
13 m-LAD
d-RCA
AdTβ-ExR 
PBS
1x109 3.0
3.5
alive
302 Exp. Mol. Med. Vol. 34(4), 299-307, 2002MO). Tissue sections were subsequently counterstained
with hematoxylin-eosin. 
Reverse transcription PCR (RT-PCR)
Total cellular RNA from each arterial segments was
isolated using RNeasy mini kit (Qiagen, Germany). For
reverse transcription and PCR reactions, a Perkin-
Elmer/Cetus DNA thermal cycler (Foster city, CA) was
used. Two microgram of total RNA was reverse
transcribed in a 25 µl reaction containing 5 µl reverse
transcriptase buffer, 25 mM dNTPs, random hexamers
(0.5 µg/µl), 20 units RNase inhibitor and 200 units MMLV
reverse transcriptase at 37oC for 1 h followed by 5 min
at 70oC. PCR amplification was performed in a 50 µl
volume using 2 µl of the reverse transcription reaction
plus 1 unit of Taq polymerase, 10 x buffer, 0.2 mM
dNTPs, 2 mM MgCl2 and 0.2 µM of each primer under
following conditions: 94oC for 3 min; followed by 35
cycles of 94oC for 30 s, 54oC for 30 s, and 72oC for 1
min; followed by 7 min at 72oC. The primer sequences
and the expected product sizes were as follows: TGF-β
type II receptor: sense primer 5'-ACATCGTCCTGTGG-
ACGCGTA-3', antisense primer 5'-CTAGCAACAAGTC-
AGGATTGC-3' with an expected size of 450 bp; and 28
S RNA: sense primer 5'-TTAAGGTAGCCAAATGCCTC-
G-3', antisense primer 5'-CCTTGGCTGTGGTTTCGCT-
3' with an expected size of 102 bp. PCR products were
separated on a 1.2% agarose gel, stained with ethidium
bromide, and analyzed using an image analyzer
(Bioprofil, Viber Lourmat, France).
Immunostaining
Identification of soluble TGF-β type II receptor was
assessed by using direct immunofluorescent staining to
detect human IgG fused to this soluble receptor with
fluorescein isothiocyanate (FITC)-conjugated rabbit anti-
human IgG (Dako, Carpinteria, CA). Briefly, frozen
sections were dried, placed in PBS for 10 min, incu-
bated with FITC-conjugated rabbit anti-human IgG at
room temperature for 1 h, rinsed with PBS for 10 min,
and mounted with glass coverslip. The immunostained
slides with FITC conjugated anti-human IgG complex
were assessed by using immunofluorescent microscope,
and photographed immediately. T cells were identified in
specimens taken at both 1 week and 4 weeks after gene
delivery by immunohistochemical staining with rabbit
polyclonal anti-human CD3 antibodies (Dako). 
Results
Identification of human TGF-β type II receptor gene 
Three pigs were sacrificed 1 week after gene delivery to
analyze the efficiency of gene transfection. As shown in
Figure 1, RT-PCR products from porcine coronary artery
(d-LAD) injected with AdTβ-ExR of 1 x 109 pfu showed a
definite band of human TGF-β type II receptor gene
product, while artery (p-LAD) injected with that of 5 x 108
pfu showed a faint band of the gene product. Neither
arterial segment adjacent to AdTβ-ExR (1 x 109 pfu)
injected site (m-LAD), as shown in Figure 1, nor artery
injected with AdTβ-ExR of 1 x 108 pfu (data not shown)
revealed any detectable band. These results suggest that
Figure 1. RT-PCR analysis for detection of a transferred soluble TGF β type
II receptor mRNA in each porcine coronary artery. RT-PCR analysis showed
the amplified gene product from the distal LAD injected with 1x109 pfu
AdTβ-ExR. Proximal LAD injected with 5x108 pfu AdTβ-ExR showed a faint
band of the soluble receptor gene product, whereas mid LAD in between
two injection sites showed no transgene product. Note the bands of 28S
RNA product from each arterial segment which verify a quantitative analysis
of human TGF-β type II receptor gene product.
Figure 2. Immunohistochemical staining of porcine coronary arteries for detection of soluble TGF β type II receptor with FITC-conjugated rabbit anti-human IgG.
A) There are multiple dispersed tiny immunofluorescent positive particles (marked as arrows) of soluble TGF β type II receptor located in media and adventitia
of the distal LAD injected with 5 x 108 pfu AdTβ-ExR. (B) and (C), Right coronary artery in the same pig, remote from distal LAD, shows no discernable soluble
receptor: with (B) and without (C) FITC conjugated antibody, bar = 50 µm.
In vivo gene delivery using Infiltrator 303successful local gene delivery of human TGF-β type II
receptor was carried out using an Infiltrator without any
significant dissemination of adenovirus vector. RT-PCR
products of 28S RNA from each artery showed a band of
equal density, which verify a quantitative analysis of
human TGF-β type II receptor gene product.
Identification of soluble receptor 
Direct immunofluorescent staining with use of FITC-
conjugated rabbit anti-human IgG identified the soluble
TGF-β type II receptor, and, as shown in Figure 2,
coronary artery injected with 5 x 108 pfu AdTβ-ExR
showed multiple dispersed immunofluorescent positive
soluble receptor-antibody complex particles in around
media and adventitia. The soluble TGF-β receptor was
more widely dispersed comparing with the distribution of
β-galactosidase. On the other hand, remote arteries
including remote coronary artery and thoracic aorta
showed no discernable immunofluorescent positive par-
ticles. Thus, it is conceivable that the soluble receptor
delivered by certain range of adenoviral vector could be
expressed locally at the site of gene delivery without any
significant spread to remote sites. 
Identification of β-galactosidase 
Gene transfection was also studied by immunohisto-
chemical assay of β-galactosidase in the arteries injected
with two different titers of AdCALacZ (2.5 x 107 pfu and
2.5 x 108 pfu). As shown in Figure 3, the expression of β-
galactosidase was noted locally in around outer media and
adventitia at the arterial segment injected with AdCALacZ of
2.5 x 108 pfu, and there was no significant spread of β-
galactosidase at remote arterial segments. Coronary ar-
terial segments injected with 2.5 x 107 pfu AdCALacZ had
no expression of β-galactosidase (data not shown). 
Inflammation 
CD3+ T cells were infiltrated around adventitia and, with
less extent, media in arteries 1 week after injection with
either AdCALacZ or AdTβ-ExR (Figure 4). More T cells
were infiltrated in segments injected with AdCALacZ
comparing to that with AdTβ-ExR. The numbers of
infiltrated T cells tend to decrease over time after gene
delivery, and there were only a few T cells present in
arteries 4 weeks after injection of adenovirus vector
(data not shown). The remote coronary artery has no
CD3+ T cells as shown in Figure 4.
Procedural complications
As shown in Table 1, ten pigs survived after catheter-
Figure 3. Porcine coronary artery injected with 2.5x108 pfu AdCALacZ
shows β-galactosidase activity identified by histochemical staining with the
substrate X-gal. Note the blue stained area showing the expression of β-
galactosidase in the outer media and adventitia. Counter staining with
hematoxylin-eosin. Arrow head shows external elastic lamina. Ad,
adventitia; L, lumen; M, media; bar=50 µm.
Figure 4. Infiltrated CD3+ T cells in the porcine coronary arteries injected with each adenovirus vector. Arteries 1 week after injection with either AdCALacZ
(2.5x108 pfu) (A) or AdTβExR (5x108 pfu) (B) show CD3+ T cells (brown color) infiltrated in adventitia, whereas remote control artery (C) has no CD3+ cells.
Counterstaining with hematoxylin; bar = 50 µm.
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procedure. Two pigs died due to ventricular tachycardia
induced by intimal dissection and subsequent total
occlusion of the artery. Pathological study of these
arteries revealed disruption of either external elastic
lamina or, less frequently, of tunica media with
hemorrhage in ruptured space (Figure 5B and 5C).
Minimal dissection at the external elastic lamina without
any significant compromise of coronary circulation was
noted in one artery. In addition, interruption of the
endothelial layer and internal elastic lamina, miniscule
channel penetrating into media with protrusion of nest of
cells in a loose ECM, medial thickening caused by edema,
and interrupted medial layer were also noted (Figure 5A).
One pig died due to the failure of deballooning of the
Infiltrator and subsequent intravascular occlusive thro-
mbosis. Transient coronary arterial spasm responding to
intracoronary nitrate injection occurred in three arterial
segments. Ventricular tachycardia associated with arte-
rial spasm were often fatal in our study: only one of four
pigs with ventricular tachycardia survived after direct
current cardioversion. 
Discussion
We studied the efficacy and complications of adenovirus
mediated local intravascular delivery of a soluble TGF-
β type II receptor using an Infiltrator in a porcine
coronary arterial model known to be very similar to that
of human (Muller et al., 1992). Expression of β-
galactosidase delivered by an Infiltrator was mostly
localized around outer media and adventitia, which
seems to be related with the height (279 µm) of injector
ports. And similar observations were reported by other
studies (Morishige et al., 2000; Kingston et al., 2001).
Our study suggested that no significant dissemination of
adenovirus occurred, since transgene, ectodomain of
human TGF β type II receptor mRNA, was localized in
the injection segment. And this finding is consistent with
the previous study (Feldman et al., 1995). The soluble
TGF-β receptor delivered by injection of 5 x 108 pfu
AdTβ-ExR was more widely dispersed in around media
and adventitia comparing with that of β-galactosidase,
but neither TGF-β receptor nor β-galactosidase was
found at remote arterial segments. The same soluble
Figure 5. Procedural complications in porcine coronary arteries treated with Infiltrator. (A) Rupture ( marked as an arrow ) of intima and underlying internal elastic
lamina in a porcine coronary artery 1 week after injection of adenovirus. Note the nest of cells in the loose ECM protruded into the lumen through this ruptured
layers. (B) and (C) Cases of rupture occurred in external elastic lamina (B) and media (C) in the arteries treated with Infiltrator. Note the hemorrhagic fluid (*)
accumulation in the ruptured space. (D) Normal porcine coronary artery stained with Movat pentachrome staining. Ad, adventitia; IEL, internal elastic lamina;
EEL, external elastic lamina; L, lumen; M, media. Hematoxylin-eosin staining (A, B, C); bar = 100 µm.
In vivo gene delivery using Infiltrator 305receptor is capable to reach remote areas by means of
systemic circulation in other study. Intramuscular in-
jection of same amount of AdTβ-ExR (5 x 108 pfu) in a
mouse showed that an increase of concentration of this
soluble receptor was noted not only in the serum, but
also in the remote organ (Sakamoto et al., 2000). This
discrepancy is probably caused by the difference of
dilution of soluble TGF-β receptor between two different
animal models. Our animal model (pig, ≅30 kg) which is
much larger than that of the other study (mouse, ≅30 g)
should enable the soluble receptor to dilute significantly
in the systemic circulation. 
A replication-defective adenoviral vector has several
advantages over other vectors for in vivo gene transfer
to intravascular model. The adenovirus vectors, unlike
the retroviruses, are effective in delivering gene in non-
dividing vascular cells (Wivel et al., 1998). Vascular
cellular replication rate is known to be very low (mostly
0-1%) in human arterial tissue, which is true in human
restenotic arterial tissue as well as in primary athero-
sclerotic plaque (Gordon et al., 1990; OBrien et al.,
1993; Chung et al., 2002). Cell replication rate is also
known to be low (≤ 5%) in injured rabbit artery (Strauss
et al., 1994) and in our porcine coronary stent neointima
specimens (unpublished data). In addition, adenoviral
vectors are stable in the blood stream, and adenoviral
DNA is not integrated into the host cell chromosome.
An adenoviral vector expressing the ectodomain of
the type II TGF-β receptor (AdTβ-ExR) inhibits the
action of TGF-β by adsorbing TGF-β, but it may act as
a dominant negative receptor (Sakamoto et al., 2000).
As a possible mechanism of dominant negative mu-
tation, Chen et al. suggested that truncated and wild
type receptor form heterodimers and abrogate further
sig-naling via either accelerated degradation of the
hetero-dimers or impaired transport of the wild type
receptor to the cell surface that accounts for reduced
level of endogenous type II receptor. In addition, trun-
cated type II receptor may form a heterodimer with type
I receptor preventing an interaction of the endogenous
type II receptor and type I receptor. Therefore, it is
noteworthy that due to the intrinsic competitive nature of
dominant negative mutants the expression level of
soluble receptor needs to greatly exceed that of the
endogenous receptor (Chen et al., 1993).
Host immune response and dose-dependent in-
flammatory and cytopathic effects inhibit adenoviral
gene expression, and impose limitations in gene de-
livery (Grub et al., 1994; Feldman et al., 1995; Wivel et
al. 1998). Therefore identification of viral titer that is
effective in gene expression with minimal inflammatory
reaction seems to be important. Gene transfer assay
with different titers of each adenoviral vector showed
that the minimum adenoviral titers for effective gene
expressions were 5 x 108 pfu for AdTβ-ExR and
2.5 x 108 pfu for AdCALacZ in our study. And arterial
segments 1 week after adenoviral vector mediated gene
delivery showed CD3+  T cells infiltrated in the area of
adventitia and media, and the numbers of infiltrated T
cells tend to decrease over time. This is consistent with
other study that intramuscular injection of E1 deleted
adenoviral vector expressing β-galactosidase in a mice
induced a significant inflammatory response charac-
terized by mononuclear cell infiltration and degeneration
of muscle fiber (Yang et al., 1996). This study also
showed that inflammation, peaked at 17 days after gene
transfer, slowly diminished to baseline over several
months, and that the expression of transgene
diminished to undetectable level within 30 days. Cellular
immunity dependent on CD4+ and CD8+ T cells limit the
duration of vector derived transgene expression, and
humoral immunity also plays a role in diminishing gene
transfer following a second administration of vector
(Yang et al., 1994; Yang et al., 1995; Yang et al., 1996).
Activation of CD8+ T cells is known to be induced by
viral capsid proteins, newly expressed viral proteins,
and the transgene product (Yang et al., 1996). In our
study, infiltrated CD3 positive T cells were more in
segments injected with AdCALacZ comparing to that
with AdTβ-ExR. This finding is consistent with other
study (Kingston et al., 2001), and should be considered
in the context with the concept that β-galactosidase has
the potential for eliciting immune responses (Danko et
al., 1994; Yang et al., 1996). 
The Infiltrator was developed as a tool for local
intravascular delivery of drug, and has been used in
animals (Barath et al., 1997; Varenne et al., 1998;
Morishige et al., 2000; Kingston et al., 2001) and rarely in
human (Pavlides et al., 1997). Our study showed that
catheter-based local in vivo adenovirus mediated gene
transfer using an Infiltrator is, in general, effective and
feasible in an arterial segment characterized by diameter
of at least 2.5 mm, light tortuosity, minimal angulation
(< 45o), and free of side branch. However procedure-
related complications such as medial dissection with
hemorrhage and subsequent vasospasm occurred in 4
arteries among 24 treated arteries in our study. We
occasionally observed that some injector ports of Infiltrator
were obliterated after use, which may be a possible cause
for the hydraulic dissection due to excess of fluid accu-
mulation at the limited vascular space. Therefore further
studies aimed for the improvement of feasibility and safety
are necessary before the appli-cation in human. 
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